Nucleic acid approaches to antibody-based therapeutics for COVID-19: A perspective - 05/09/20
Doi : 10.1016/j.jaci.2020.06.022
Elizabeth Parzych, PhD, David B. Weiner, PhD ⁎ 
Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pa
∗Corresponding author: David B. Weiner, PhD, Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104.Vaccine and Immunotherapy CenterThe Wistar Institute3601 Spruce StPhiladelphiaPA19104
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : COVID-19, SARS-CoV-2, monoclonal antibody, nucleic acid, gene delivery
Le texte complet de cet article est disponible en PDF.
Plan
| Disclosure of potential conflict of interest: D. B. Weiner discloses the following paid associations with commercial partners: GeneOne (consultant), Geneos (Advisory Board), Astrazeneca (Advisory Board, speaker), Inovio (BOD, SRA, Stock), Pfizer (speaker), Merck (speaker), Sanofi (Advisory Board), and BBI (Advisory Board). E. Parzych declares no relevant conflicts of interest. |
© 2020
Publié par Elsevier Masson SAS.
Vol 146 - N° 3
P. 537-540 - septembre 2020 Retour au numéro
Article précédent
- The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
- Asthmatic patients in COVID-19 outbreak: Few cases despite many cases
- Marco Caminati, Carlo Lombardi, Claudio Micheletto, Elena Roca, Barbara Bigni, Fabiana Furci, Domenico Girelli, Gianenrico Senna, Ernesto Crisafulli
Bienvenue sur EM-consulte, la référence des professionnels de santé.